Brian Park, PharmD

Drug Information Specialist https://www.psychiatryadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

General Medicine

Statin Use Linked to Reduced Death Risk in Hospitalized COVID-19 Patients

Brian Park, PharmD

August 31, 2021

Study authors analyzed data from 10,541 hospitalized patients with active COVID-19 disease to evaluate the relationship between the use of statins and COVID-19 outcomes.

ADHD

Azstarys, a Novel ADHD Treatment, Now Available

Brian Park, PharmD

August 6, 2021

Azstarys consists of serdexmethylphenidate, a prodrug of dexmethylphenidate, co-formulated with immediate-release dexmethylphenidate.

General Psychiatry

Janssen COVID-19 Vaccine Fact Sheet Updated With Guillain-Barre Syndrome Warning

Brian Park, PharmD

July 16, 2021

The FDA has updated the fact sheet for the Janssen COVID-19 vaccine to include information related to an increased risk of Guillain-Barré syndrome.

General Psychiatry

Pfizer-BioNTech: Update on COVID-19 Booster Shot; Reformulated Vaccine in the Works

Brian Park, PharmD

July 14, 2021

An updated version of the Pfizer-BioNTech COVID-19 vaccine that targets the full spike protein of the Delta variant is also in the works.

Alzheimer Disease and Dementia

Aduhelm Label Update Clarifies Patient Population Studied in Trials

Brian Park, PharmD

July 13, 2021

The treatment, which is administered as a monthly intravenous infusion, binds to aggregated β-amyloid and promotes removal of amyloid from the brain.

General Psychiatry, News

Risk of Falsely Low Results Prompts Recall of Lead Tests

Brian Park, PharmD

July 12, 2021

The FDA is concerned that obtaining falsely low test results may lead to inappropriate follow-up assessments, which may result in patient harm.

Alzheimer Disease and Dementia, News

Donanemab Granted Breakthrough Tx Status for Alzheimer Disease

Brian Park, PharmD

July 1, 2021

Donanemab is an investigational antibody therapy that targets a modified form of deposited amyloid-β peptide called N3pG.

Alzheimer Disease and Dementia

Lecanemab Gets Breakthrough Tx Status for Alzheimer Disease

Brian Park, PharmD

June 30, 2021

Lecanemab (BAN2401) is an investigational anti-amyloid beta protofibril antibody
for the treatment of Alzheimer disease.

General Psychiatry

Veklury Cuts Mortality Risk in Hospitalized COVID-19 Patients, According to Real-World Data

Brian Park, PharmD

June 29, 2021

Veklury is currently approved for the treatment of COVID-19 in patients aged 12 years and older (weighing at least 40kg) requiring hospitalization.

General Psychiatry

FDA: Systemic Side Effects Reported After Hand Sanitizer Application

Brian Park, PharmD

June 21, 2021

The Agency reviewed case reports from the FAERS database and calls from US poison control centers related to systemic symptoms after applying alcohol-based hand sanitizers to the skin.

Next post in General Psychiatry